Exocytosis of hormones occurs through the fusion of large dense-core secretory vesicles with the plasma membrane. This highly regulated process involves key proteins such as SNAREs (soluble N-ethylmaleimidesensitive fusion protein-attachment protein receptors) and also specific lipids at the site of membrane fusion. Among the different lipids required for exocytosis, our recent observations have highlighted the crucial role of PA (phosphatidic acid) in the late stages of membrane fusion in various exocytotic events. An RNAi (RNA interference) strategy coupled with the detection of PA in living cells has pointed to plasma membraneassociated PLD1 (phospholipase D 1 ) as the main producer of PA in response to secretagogue stimulation. We have identified several GTPases which regulate the activation level of PLD 1 in neuroendocrine cells. Finally, RSK2 (ribosomal S6 kinase 2) appears to phosphorylate and regulate the activity of PLD 1 in a calcium-dependent manner. Altogether our results have unravelled a complex set of regulatory pathways controlling the synthesis of fusogenic lipids at the secretory granule fusion site by PLD 1 .
Introduction
Although occurring at different speeds, both neurotransmitters and hormones are released through a very similar process called regulated exocytosis that involves the fusion of specialized cargo-containing vesicles with the plasma membrane. This process is governed by a set of proteins called SNAREs (soluble N-ethylmaleimide-sensitive fusion protein-attachment protein receptors). Overwhelming evidence accumulated over the last decade indicates that the SNARE proteins syntaxin, synaptobrevin and SNAP-25 (25 kDa synaptosome-associated protein) are intimately involved in the final steps of membrane fusion [1] . The most popular current model suggests that a tight coiledcoil complex between these proteins pulls the participating membranes together. In this model, the energy liberated by the formation of the SNARE complex is used to overcome the energy barrier of lipid rearrangements during fusion.
The role of lipids in membrane fusion is less well understood, but recent findings indicate that in addition to the well-known signalling function of phosphatidylinositol derivatives, lipids might be important for the fusion process through their shape [2] . In vitro, cone-shaped lipids,
PLD1 in neuroendocrine exocytosis
The role of PLD in secretion was originally investigated by using primary alcohols, which interfere with the PLDinduced production of PA, and by expressing catalytically inactive PLD mutants. Both treatments were found to profoundly impair hormonal release in chromaffin and PC12 cells [4, 6] . Immunoblot analysis of chromaffin cell extracts using isoform-specific antibodies indicated that PLD1 was enriched in subcellular fractions containing plasma membrane markers, whereas PLD2 was not detected [4] . In agreement, immunofluorescence of cultured chromaffin cells revealed that PLD1 co-localized with the plasma membrane marker SNAP-25 [4] . Analysis of individual exocytotic events in chromaffin cells microinjected with catalytically inactive mutants indicated that the PLD2 mutant had no effect, whereas the PLD1 mutant apparently reduced the initial rate of release, possibly reflecting a defect in a late step of exocytosis prior to fusion pore formation and/or expansion [4] . This finding was supported by experiments performed in Aplysia neurons. After microinjection of catalytically inactive PLD1, actetylcholine release was inhibited and, in this case, the number of active presynaptic release sites was altered without any changes in the probability or the quantum released [9] .
More recently, specific RNA silencing in PC12 cells has shown that endogenous PLD1 depletion had little effect on basal PLD activity, but strongly inhibited PLD activation induced by different secretagogues. Thus PLD1 appears to be the PLD isoform activated during calcium-regulated exocytosis [13] . Capacitance recordings from chromaffin cells expressing PLD1 siRNA (small interfering RNA) indicated that PLD1 controls the number of fusion-competent secretory granules docked at the plasma membrane without affecting earlier recruitment steps [13] . In agreement with these findings, PLD1 depletion also reduced exocytosis from pancreatic β-cells [14, 15] , mast cells [7, 16, 17] and endothelial cells [18] .
Using subcellular fractionation, we were able to show that PLD activity was markedly increased in plasma membrane fractions from stimulated cells compared with resting cells [6] . Like catecholamine release, secretagogue-dependent PLD activation required an increase in the intracellular calcium level [6] . More recently, using the molecular probe Spo20p-GFP (green fluorescent protein) that specifically binds to PA, the product of PLD activity, PA was observed to accumulate at exocytotic sites [13] . Indeed, a morphometric analysis revealed a 3-fold increase in the amount of PA probe present at the plasma membrane sites where granules appear to be morphologically docked compared with regions devoid of secretory granules [13] . The recruitment of Spo20p-GFP at the plasma membrane of stimulated cells was specifically impaired in cells depleted of PLD1, arguing that PLD1 is responsible for the synthesis of PA at the exocytotic site in stimulated neuroendocrine cells.
The precise role of PLD-produced PA at the site of fusion remains an open question. PA is a multifunctional lipid that can serve as a protein attachment site, activate selected enzymes or be transformed into other signalling lipids. PA is also a cone-shaped lipid and a predicted effect of its generation at the granule docking site would be to promote a negative curvature in the cytoplasmic leaflet of the plasma membrane, thereby facilitating the formation of the hemifusion intermediates required for the fusion of two membranes [3] . The local generation of PA due to the activation of PLD1 at the plasma membrane should thus induce a negative curvature of the cytoplasmic leaflet ( Figure 1 ). Along this same line, the defects in hormone release caused by reducing PLD1 expression can be reversed by adding a lipid such as lysophosphatidylcholine that favours positive membrane curvature to the outer leaflet of the plasma membrane [13] . These results led us to propose that PA triggers or facilitates hemifusion intermediates between docked granules and the plasma membrane, thereby directly promoting the formation of exocytotic fusion pores. Most interestingly, recent in vitro experiments indicate a direct role for calcium in the ability of lipids to affect membrane curvature [2] . Thus lipids as well as proteins may sense cytosolic calcium and thereby define calcium-triggered steps in regulated exocytosis.
The biophysical properties of PA imply that it should rapidly disperse within planar membranes rather than concentrate at specific sites. One possible explanation for the accumulation of PA at the exocytotic site is the occurrence of a PA-binding site that prevents PA diffusion. Recently, such binding of PA to a protein with a PA-binding motif has been identified in the plasma membrane-associated SNARE protein syntaxin-1 [19] . A mutation in the polybasic juxtamembrane region of syntaxin-1, which prevents binding to acid phospholipids such as PA, strongly affected the exocytotic response of chromaffin and PC12 cells, suggesting that PA binding may be required for the function of syntaxin [19] . The observations that the secretory defect seen in cells expressing an acidic phospholipid-binding-deficient syntaxin-1 could be completely rescued by overexpressing PLD1 is the first evidence supporting the idea that PA is critical for SNARE-mediated fusion events. In agreement, in vitro experiments have revealed that PA present in a t-SNARE (target SNARE)-containing membrane promoted fusion with a v-SNARE (vesicle SNARE)-containing membrane [20] . The exact nature of the lipid organization found at the exocytotic sites remains, however, to be precisely defined. For example, the ability of lipid rafts to sequester specific proteins and exclude others makes them ideally suited to spatially organize and concentrate components of the exocytotic machinery [21] .
Regulators of PLD activity in neuroendocrine exocytosis
In neuroendocrine cells, PLD1 is activated in response to various secretagogues to produce PA at the granule docking sites on the plasma membrane [13] . PLD1 is a multimodule protein that displays a very low basal activity and was shown both in vitro and in vivo to be fully activated by a combination of small GTPases and protein kinases [22] .
Using a variety of techniques, we have shown that a number of small GTPases are activated after secretagogue stimulation of chromaffin and PC12 cells [23] [24] [25] [26] [27] . Among these GTPases, the Arf (ADP-ribosylation factor), Ral and Rho family members are of particular interest owing to their implication in regulated exocytosis and their ability to activate PLD1 in vitro. By expressing various inactive or constitutively active mutants in neuroendocrine cells, ARF6, Cdc42 (cell division cycle 42), Rac1 and RalA were found to exert a positive influence on neuroendocrine exocytosis [24] [25] [26] 28] . These observations have been corroborated in PC12 cells in which the levels of endogenous GTPases were reduced by up to 90% by expressing shRNA (small hairpin RNA) [25] [26] [27] [28] . In order to test the link between PLD1 activation and these GTPases, we used a fluorimetric PLD assay in cellular extracts and the PA-binding probe in living cells. The increase in PLD activity observed in stimulated PC12 cells was greatly reduced in cells depleted of ARF6, Rac1 and RalA, whereas depletion of ARF1, Cdc42 and RhoA had no effect (Figure 2 ) [25] [26] [27] [28] . At the same time, depletion of ARF6 and Rac1 almost completely prevented the recruitment of Spo20p-GFP at the plasma membrane in stimulated cells [27, 28] . Altogether this suggests that endogenous ARF6, Rac1 and RalA are involved in secretagogue-dependent PLD activation at the exocytotic site.
Interestingly, expression of the ARF6(N48I) mutant that has specifically lost its ability to activate PLD1 inhibited secretion in PC12 cells, implicating PLD1 in the same regulatory pathway as ARF6 during exocytosis [24] . In line with this hypothesis, overexpression of an ARF6(N48I) construct resistant to siRNA failed to rescue secretion in ARF6-depleted cells, whereas wild-type ARF6 almost completely restored it [27] . Expression of a series of RalA mutants selectively impaired in their ability to activate downstream effectors demonstrated that PLD1 activation was essential for the activation of secretion by GTP-loaded RalA, highlighting another link between PLD activation and exocytosis. Finally, our results indicate that RalA coprecipitates with ARF6 and PLD1 in response to membrane depolarization, suggesting that the two GTPases may activate PLD1 synergistically after calcium influx through voltagegated calcium channels. Interestingly, RalA is known to contain a calmodulin-binding site, and Ca 2+ -calmodulin binding directly stimulates GTP loading and RalA activation [29] . Thus RalA may be the missing link that integrates calcium signals with PLD1 and its lipid-modifying activity at exocytotic sites.
Interestingly, PLD1 is also regulated by phosphorylation in many cellular processes [30] , which could be in itself sensitive to intracellular calcium levels. This is especially relevant since calcium is the main trigger of exocytosis. Thr 147 in PLD1, known to be phosphorylated by PKC (protein kinase C), also lies within a consensus phosphorylation site for the RSKs (ribosomal S6 kinases), which are activated through the ERK (extracellular-signal-regulated kinase) pathway. Using an RNAi (RNA interference) strategy, we recently observed that RSK2 plays a crucial role in calciumregulated exocytosis of large dense-core secretory granules [31] . RSK2 was also found to co-precipitate with PLD1, phosphorylate PLD1 and stimulate its enzymatic activity in response to secretagogues [31] . Most importantly, PLD1 phosphorylation by RSK2 is essential for the function of PLD1 in the exocytotic machinery, namely the production of fusogenic PA at granule docking sites on the plasma membrane [32] . In humans, loss-of-function mutations in the gene encoding RSK2 leads to the CLS (Coffin-Lowry syndrome), which is characterized by severe growth and mental retardation [33] . Our studies establishing a functional link between RSK2 and PLD1 during exocytosis provide some insights for understanding the molecular mechanisms underlying the neuronal clinical features of CLS, and support the idea that part of the growth and mental retardation phenotypes observed in CLS patients may be associated with defects in hormone or neurotransmitter release.
Conclusion
Chromaffin granule exocytosis differs in many physiological aspects from neuronal synaptic vesicle exocytosis. While modulatory mechanisms clearly operate for particular physiological functions, it is now clear that neurons and neuroendocrine cells use similar proteins to mediate and regulate the docking and fusion of synaptic vesicles and granules with the plasma membrane. The lipid composition of membranes at fusion sites is tightly controlled by PLD production of PA that may play a decisive role in the late stages of membrane fusion by providing the membrane curvature required for merging membranes. GTPase and kinase signalling occurs in neurons and neuroendocrine cells and they are likely to represent additional components of the conserved machinery for hormone and transmitter release, in part through the regulation of PLD. In recent years, intimate links between ARF, Ral and Rac GTPases have emerged, along with the evidence that many regulators and effectors of the ARF and Rho families are often intertwined [34] . These functional relationships between GTPases and kinases could provide neurosecretory cells with a way of tightly co-ordinating vesicular traffic and fusion with the plasma membrane and actin dynamics, thereby controlling the finely tuned secretory machinery. Furthermore, mutations in the genes encoding RSK2 and the Rac regulator oligophrenin-1 have been shown to cause mental retardation-associated pathologies [35] . The challenge in the future will be to determine whether regulated secretion in situ obeys similar rules and mechanisms.
